

Original research

# Sex differences in endovascular thrombectomy outcomes in large vessel occlusion: a propensity-matched analysis from the SELECT study

Johanna T Fifi,<sup>1</sup> Thanh N Nguyen <sup>2</sup>, Sarah Song,<sup>3</sup> Anjail Sharrief,<sup>4</sup> Deep Kiritbhai Pujara <sup>5</sup>, Faris Shaker <sup>4</sup>, Lauren E Fournier,<sup>6</sup> Erica M Jones,<sup>7</sup> Colleen G Lechtenberg,<sup>8</sup> Sabreena J Slavin,<sup>8</sup> Nneka L Ifejika,<sup>7,9,10</sup> Maria V Diaz,<sup>11</sup> Sheryl Martin-Schild,<sup>12,13</sup> Joanna Schaafsma,<sup>14</sup> Jenny P Tsai,<sup>15</sup> Anne W Alexandrov,<sup>16</sup> Stavropoula I Tjoumakaris <sup>17</sup>, Amrou Sarraj <sup>5,18</sup> on behalf of the SELECT Investigators

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/neurintsurg-2021-018348>).

For numbered affiliations see end of article.

## Correspondence to

Dr Amrou Sarraj, Department of Neurology, Case Western Reserve University School of Medicine University Hospitals Neurological Institute, Cleveland, Ohio, USA; Amrou.Sarraj@uth.tmc.edu, Amrou.sarraj@uhospitals.org

Received 19 October 2021  
Accepted 6 January 2022  
Published Online First  
1 March 2022



Listen to Podcast  
[jnis.bmj.com](https://jnis.bmj.com)



© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Fifi JT, Nguyen TN, Song S, et al. *J NeuroIntervent Surg* 2023;**15**:105–112.

## ABSTRACT

**Background** Sex disparities in acute ischemic stroke outcomes are well reported with IV thrombolysis. Despite several studies, there is still a lack of consensus on whether endovascular thrombectomy (EVT) outcomes differ between men and women.

**Objective** To compare sex differences in EVT outcomes at 90-day follow-up and assess whether progression in functional status from discharge to 90-day follow-up differs between men and women.

**Methods** From the Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT) prospective cohort study (2016–2018), adult men and women (≥18 years) with anterior circulation large vessel occlusion (internal carotid artery, middle cerebral artery M1/M2) treated with EVT up to 24 hours from last known well were matched using propensity scores. Discharge and 90-day modified Rankin Scale (mRS) scores were compared between men and women. Furthermore, we evaluated the improvement in mRS scores from discharge to 90 days in men and women using a repeated-measures, mixed-effects regression model.

**Results** Of 285 patients, 139 (48.8%) were women. Women were older with median (IQR) age 69 (57–81) years vs 64.5 (56–75),  $p=0.044$ , had smaller median perfusion deficits ( $T_{max} >6s$ ) 109 vs 154 mL ( $p<0.001$ ), and had better collaterals on CT angiography and CT perfusion but similar ischemic core size (relative cerebral blood flow  $<30\%$ : 7.6 (0–25.2) vs 11.4 (0–38) mL,  $p=0.22$ ). In 65 propensity-matched pairs, despite similar discharge functional independence rates (women: 42% vs men: 48%,  $aOR=0.55$ , 95% CI 0.18 to 1.69,  $p=0.30$ ), women exhibited worse 90-day functional independence rates (women: 46% vs men: 60%,  $aOR=0.41$ , 95% CI 0.16 to 1.00,  $p=0.05$ ). The reduction in mRS scores from discharge to 90 days also demonstrated a significantly larger improvement in men (discharge 2.49 and 90 days 1.88, improvement 0.61) than in women (discharge 2.52 and 90 days 2.44, improvement 0.08,  $p=0.036$ ).

**Conclusion** In a propensity-matched cohort from the SELECT study, women had similar discharge outcomes as men following EVT, but the improvement from discharge to 90 days was significantly worse in women, suggesting the influence of post-discharge factors.

Further exploration of this phenomenon to identify target interventions is warranted.

**Trial registration number** NCT02446587.

## INTRODUCTION

Disparities in health and stroke-related outcomes between the sexes has been a longstanding area of interest to healthcare systems worldwide.<sup>1–5</sup> Women, known to live longer than men, have been shown to have higher rates of disability and worse quality of life than men after acute ischemic stroke.<sup>6,7</sup> Studies evaluating sex disparities in stroke treatments show lower rates of intravenous thrombolytic use<sup>8</sup> and risk factor reduction therapies in women.<sup>1</sup> In patients with large vessel occlusion (LVO) undergoing endovascular thrombectomy, these disparities in outcome have been controversial.<sup>9–13</sup> While a subgroup analysis from MR CLEAN (Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands) trial found that only men experienced a major benefit from endovascular thrombectomy (EVT),<sup>9</sup> a larger, pooled analysis of seven multicenter randomized clinical trials including MR CLEAN found that women derive similar benefit and good outcomes after EVT as men do relative to their respective controls.<sup>10</sup> When men and women who have undergone EVT are compared, some studies have found that women are less likely than men to be independent at 90 days,<sup>11 12</sup> while others found similar 90-day disability rates.<sup>13</sup> These studies also did not adjust for important baseline clinical or imaging characteristics<sup>9–11 13</sup> or recovery following hospital discharge<sup>9–13</sup> while evaluating whether there are disparities in functional outcomes at 90-day follow-up.

It is also unclear whether the disparities in outcomes are related to differences in baseline clinical or imaging characteristics, response to the intervention, or recovery following hospital discharge. Women are generally older when they have their first stroke. Furthermore, baseline differences in imaging characteristics and vessel diameter with

their effect on stroke outcomes by sex have been reported.<sup>14</sup> Additionally, sex-specific responses to rehabilitation<sup>15</sup> and sex-related differences in clinical, psychological, and social factors<sup>15,16</sup> that may affect functional improvements during the post-acute phase have also been described previously.

In this hypothesis-generating, secondary analysis of the Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT) prospective cohort study, we sought to evaluate the differences in EVT outcomes as measured by discharge and 90-day modified Rankin Scale (mRS) scores between men and women, and determine whether progression of functional status from discharge to 90-day follow-up beyond discharge is associated with the sex of the patient.

## METHODS

The data that support the findings of this study are available from the corresponding author on reasonable request.

### Study design and participants

This is a secondary analysis of a prospective, multicenter cohort study of imaging selection, ‘Optimizing Patient Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT): a prospective multicenter cohort study of imaging selection’ (NCT02446587). The study population, methodology, and primary results of the SELECT trial have been published.<sup>17,18</sup> Patients with acute ischemic stroke and anterior circulation LVO who presented up to 24 hours from symptom onset at nine US study sites were enrolled between January 2016 and February 2018. Major inclusion criteria for the study were (1) adults  $\geq 18$  years with acute ischemic stroke, (2) National Institutes of Health Stroke Scale (NIHSS) score  $\geq 6$  at presentation, (3) LVO on CT angiography (CTA) in anterior circulation (in the internal carotid artery (ICA), middle cerebral artery (MCA) M1/M2 segments), and (4) no or minimal deficits at baseline (mRS score 0–1). All patients received a standardized pre-thrombectomy imaging protocol with non-contrast CT, CTA, and CT perfusion with automated processing using RAPID software (iSchemaView, Menlo Park, California, USA). Imaging studies were evaluated by an independent neuroimaging core laboratory blinded to clinical outcomes and enrollment site. Decision to proceed with thrombectomy versus medical management alone was at the discretion of the site investigators. All patients received best medical management as defined by the contemporary American Heart Association/ American Stroke Association guidelines, including use of IV thrombolysis with alteplase within 4.5 hours of last known well if applicable.<sup>19</sup> Endovascular thrombectomy constituted attempted clot retrieval using a stent retriever, aspiration device, or a combination thereof. For the purpose of this analysis, men and women were matched based on baseline clinical and imaging characteristics to compare study outcomes.

### Ethical approval disclosure

The study protocol was approved by the institution review board (IRB) at each participating site prior to the start of the study, and it was registered at ClinicalTrials.gov (NCT02446587). The ethical committees that approved the study are: UT McGovern Medical School – Houston, Texas - UT Committee for Protection of Human Subjects (HSC-MS-15-0337); Emory University – Atlanta, Georgia: Emory University IRB (CR1\_IRB00083782); Florida Hospital – Orlando, Florida: Florida Hospital IRB (699 641–2); Stanford University, Palo Alto, California - Stanford IRB (37774); St Louis University – St Louis, Missouri - SLU IRB (26092); Kansas University – Kansas City, Kansas: KUMC

IRB (IRB00000161); Valley Baptist Hospital – Harlingen, Texas - MetroWest Medical Center IRB (2015–095); Riverside Methodist Hospital – Columbus, Ohio: WIRB (1160694); and Well-Star Health System - Marietta, Georgia: WIRB (1162531). All study participants or their legally authorized representatives provided written informed consent prior to data entry into the SELECT database up to 7 days after the procedure.

### Imaging evaluation

The imaging evaluation included preprocedure CT Alberta Stroke Program Early CT Score (ASPECTS), modified collateral score, CT perfusion (cerebral blood flow, Tmax maps), hypoperfusion intensity ratio (Tmax >10s volume/Tmax >6s volume), modified Thrombolysis in Cerebral Infarction<sup>20</sup> on cerebral angiogram, and final infarct volume, as measured on postprocedure DWI sequences using manual segmentation of the region of interest. If postprocedure MRI was not available, final infarct volume was measured on non-contrast CT.

### Study outcomes

The primary outcome was the 90-day mRS score, assessed by reviewers, blinded to treatment allocation and imaging findings, in-person (preferred) or over a phone call if an in-person visit was not feasible. Functional independence, defined as mRS score of 0–2 was also evaluated. Safety endpoints included symptomatic intracerebral hemorrhage, defined as worsening of NIHSS score of 4 or more with evidence of any intracerebral hemorrhage on follow-up imaging,<sup>21</sup> neurological worsening defined as worsening of NIHSS score of 4 or more at 24 hours from presentation NIHSS score, and mortality at 90 days. The difference between functional status at discharge and at 90-day follow-up as measured by mRS was also evaluated.

### Statistical analysis

Patients who received EVT were stratified by sex; their baseline clinical and imaging characteristics were described and compared. Univariable comparisons were made using Pearson’s  $\chi^2$  test or Fisher’s exact test for categorical variables and Student’s t-test or Wilcoxon rank sum test for continuous variables, where appropriate. A propensity-matched analysis was also undertaken, using age, NIHSS score, time from last known well to procedure, occlusion location, ischemic core volume, hypoperfusion intensity ratio, collaterals score, coronary artery disease congestive heart failure and atrial fibrillation history to ensure a balanced 1:1 sample of men and women, using nearest neighbor match for probability of characteristics associated with sex. Since there was a high degree of correlation between ischemic core at baseline and penumbra (Tmax >6s) at baseline, only ischemic core at baseline was used to create the model for calculation of propensity scores.

Difference in functional outcome by sex was evaluated using multivariable ordinal logistic regression models adjusting for potential confounders—age, race, NIHSS score at presentation, serum glucose, IV tissue plasminogen activator status, transfer status, ischemic core volume, clot location, time from last known well to groin puncture, time from groin puncture to reperfusion/end of the procedure, and discharge disposition. Point estimates and 95% confidence intervals were reported for common OR. Effect of sex on functional independence (mRS score 0–2) was also assessed using a multivariable logistic regression model with the aforementioned covariates, and OR with 95% CI was reported.

To evaluate the improvement from discharge to 90-day follow-up in mRS scores in men and women, we analyzed how mRS score at discharge and at 90-day follow-up changed using a repeated-measure, mixed-effects regression model with a linear approximation of mRS scores. Predicted mRS scores (estimated marginal means) with *p* value for interaction terms were reported to identify if the improvement in mRS scores from discharge to 90-day follow-up differs between the two sexes.

STATA 15 (StataCorp. 2017. Stata Statistical Software: Release 15. College Station, Texas: StataCorp LLC.) was used for all statistical analyses. All *p* values were two-sided and *p*<0.05 was considered statistically significant.

## RESULTS

### Clinical and imaging baseline characteristics: comparison by sex

Of 361 patients enrolled in the SELECT study, 285 received EVT and were included in the analysis. 146 (51.2%) were men and 139 (48.8%) were women. A summary of baseline clinical and imaging characteristics of the overall cohort of patients receiving EVT stratified by sex is provided in [table 1](#). Women included in the study cohort were older (median years (IQR) 69 (57–81) vs 64.5 (56–75), *p*=0.044), had lower prevalence of coronary artery disease (women: 14.7% vs men: 26.6%, *p*=0.015) and a higher prevalence of atrial fibrillation (women: 40.6% vs men: 26.9%, *p*=0.015). IV thrombolysis rates did not differ; 68.5% of men as compared with 62.6% of women received IV tissue plasminogen activator (*p*=0.29). There were no differences in time from last known well to arrival at an EVT-capable hospital (men: 2.10 hours (IQR 0.90–3.90) vs women: 2.50 (1.08–4.33), *p*=0.12) and in stroke severity (NIHSS score) at presentation (men: 16 (12–20) vs women: 17 (11–22), *p*=0.44).

There were significant differences in imaging characteristics. While the median ASPECTS on non-contrast CT did not differ significantly between the two groups (men: 8 (7–9) vs women: 8 (7–9), *p*=0.87) and median ischemic core size was numerically smaller in women (men: 11.4 (0–38)mL vs women: 7.6 (0–25.2)mL, *p*=0.22); critically hypoperfused tissue (Tmax >6s) volume was significantly smaller in women (men: 154 (104–198) mL vs women: 109 (66–151.2) mL, *p*<0.001). The collaterals on CTA were similar (median (IQR) modified collateral scores: men 1 (1–2) vs women 2 (1–3), *p*=0.13), while collaterals on perfusion imaging, measured as hypoperfusion intensity ratio, were significantly better in women (men 0.51 (0.37–0.63) vs women 0.41 (0.25–0.56), *p*<0.001). The rates of achieving successful reperfusion after EVT were similar (men: 121 (82.9%) vs women: 114 (82.0%), *p*=0.85).

### Propensity-matched analysis: baseline characteristics

In a propensity-matched analysis, women and men were matched on age, NIHSS score, serum glucose at presentation, coronary artery disease, congestive heart failure, atrial fibrillation, clot location, ischemic core volume, hypoperfusion intensity ratio, collateral scores, and time from last known well to procedure. A total of 65 matched pairs were identified. A summary of the baseline characteristics of these matched pairs is provided in [table 2](#). After propensity matching, there were no differences in age (men: 64 (IQR 54–74) vs women: 67 (52–76), *p*=0.56), presentation NIHSS score (men: 15 (12–20) vs women: 16 (10–20), *p*=0.76), ASPECTS (men: 8 (7–9) vs women: 8 (7–9), *p*=0.71), or ischemic core volume (men: 6 (0–21) vs women: 12 (0–25), *p*=0.30). However, critically hypoperfused tissue (Tmax >6s)

volume was smaller in women (men: 131 (94–200.1)mL vs 109 (66–141) mL, *p*=0.007).

### Propensity-matched cohort: comparative outcomes

[Table 3](#) provides the clinical and imaging outcomes in matched pairs of men and women. The rates of functional independence at discharge (men: 31 (48%) vs women: 27 (42%), *p*=0.48) did not differ between the two groups. The distribution of functional outcomes at discharge did not differ (men: 3 (1–4) vs women: 3 (1–4), *p*=0.77). In multivariable analysis, no significant difference was observed in functional independence (aOR=0.55 (95% CI 0.18 to 1.69), *p*=0.30) or distribution of functional outcomes (common OR=0.86, 95% CI 0.44 to 1.71, *p*=0.67) between men and women. Safety outcomes were similar (neurological worsening—men: 11% vs women: 8%, *p*=0.62; symptomatic intracerebral hemorrhage—men: 8% vs women: 5%, *p*=0.72; in-hospital mortality—men: 2% vs women: 6%, *p*=0.37).

However, at 90-day follow-up, women demonstrated numerically worse functional independence rates (women: 46% vs men: 60%, aOR=0.41, 95% CI 0.16 to 1.00, *p*=0.05) and a significant ordinal shift towards worse functional outcomes in women (adjusted cOR=0.49, 95% CI 0.25 to 0.96, *p*=0.04) was observed. Additionally, the distribution of functional outcomes (men: 1 (0–4) vs women: 3 (1–4), *p*=0.09) demonstrated a trend towards statistical significance. The 90-day mortality did not differ (men: 2 (3%) vs women: 5 (8%), *p*=0.44). [Figure 1](#) demonstrates the distribution of functional outcomes on mRS score in men and women at discharge and at 90-day follow-up in the propensity-matched cohort.

The improvement in predicted mRS score from discharge to 90-day follow-up differed significantly by sex, with men exhibiting a significantly larger improvement (at discharge: 2.49, at 90-day follow-up: 1.88 for an improvement of 0.61) as compared with women (at discharge: 2.52, at 90-day follow-up: 2.44 for an improvement of 0.08, *p*=0.036). [Figure 2](#) illustrates the predicted mRS scores for men and women at discharge and how they change at 90-day follow-up, both unadjusted and adjusted for potential covariates.

## DISCUSSION

In a propensity-matched cohort of 65 pairs in this secondary analysis from the SELECT prospective cohort study, although there was no difference in the functional independence rate at discharge, men had a higher rate of 90-day functional independence than women. Additionally, the improvement from discharge to 90 days by the reduction in predicted mRS score during this interval was significantly larger in men than in women.

Multiple studies have attempted to examine sex disparities and EVT outcomes.<sup>9–13</sup> However, very few manuscripts have discussed post-discharge progression after EVT based on sexes. This manuscript represents the first analysis based on such approach using multicenter data. Also, we acknowledge and account for significant imaging differences observed between men and women due to the natural history of the disease. Furthermore, our study dataset represents the pragmatic, real-world practice from nine high-volume EVT centers in the USA.

Participation of women in large randomized controlled trials assessing endovascular thrombectomy is a topic of importance with a significant geographic variation, showing a higher proportion of representation of women in predominantly North American trials—SWIFT PRIME (52%), DAWN (55%), and DEFUSE 3 (51%), and comparatively lower in predominantly European trials—MR CLEAN (42%) and REVASCAT

**Table 1** Baseline characteristics in SELECT population treated with endovascular thrombectomy (EVT)

Factor	Level	Men	Women	P value
N		146	139	
Age, median (IQR)		64.5 (56–75)	69 (57–81)	0.044 $\alpha$
Serum glucose (mg/dL), median (IQR)		120 (105–158)	126 (110.5–161.5)	0.15 $\alpha$
Hypertension		107/145 (73.8%)	102/138 (73.9%)	0.98 $\beta$
Congestive heart failure		15/144 (10.4%)	18/137 (13.1%)	0.48 $\beta$
Coronary artery disease		38/143 (26.6%)	20/136 (14.7%)	0.015 $\beta$
Atrial fibrillation		39/145 (26.9%)	56/138 (40.6%)	0.015 $\beta$
Diabetes mellitus		40/145 (27.6%)	40/139 (28.8%)	0.82 $\beta$
Transient ischemic attack		10/146 (6.8%)	11/136 (8.1%)	0.82 $\gamma$
Prior stroke		17/145 (11.7%)	19/134 (14.2%)	0.54 $\beta$
Current smokers		24/138 (17.4%)	17/129 (13.2%)	0.34 $\beta$
Past smokers		30/137 (21.9%)	27/130 (20.8%)	0.82 $\beta$
Clot location	ICA	31/146 (21.2%)	26/139 (18.7%)	0.38 $\beta$
	MCA-M1	81/146 (55.5%)	88/139 (63.3%)	
	MCA-M2	34/146 (23.3%)	25/139 (18.0%)	
Transfer status		57/146 (39.0%)	54/139 (38.8%)	0.97 $\beta$
Time from last known well to arrival to EVT-capable center (hours), median (IQR)		2.10 (0.90–3.90)	2.50 (1.08–4.33)	0.12 $\alpha$
IV alteplase administered		100/146 (68.5%)	87/139 (62.6%)	0.29 $\beta$
NIHSS score, median (IQR)		16 (12–20)	17 (11–22)	0.44 $\alpha$
ASPECTS on baseline CT, median (IQR)		8 (7–9)	8 (7–9)	0.87 $\alpha$
Ischemic core volume (mL), median (IQR)		11.4 (0–38)	7.6 (0–25.2)	0.22 $\alpha$
Tissue volume with Tmax >6s (mL), median (IQR)		154.0 (104.0–198.0)	109.0 (66.0–151.2)	<0.001 $\alpha$
Tissue volume with Tmax >10s (mL), median (IQR)		77 (38.1–123)	43 (17–77.9)	<0.001 $\alpha$
Collateral score	0	6/146 (4.1%)	4/139 (2.9%)	0.19 $\gamma$
	1	72/146 (49.3%)	62/139 (44.6%)	
	2	56/146 (38.4%)	51/139 (36.7%)	
	3	4/146 (2.7%)	13/139 (9.4%)	
	4	8/146 (5.5%)	9/139 (6.5%)	
Modified collateral score	0	6/146 (4.1%)	4/139 (2.9%)	0.27 $\gamma$
	1	72/146 (49.3%)	62/139 (44.6%)	
	2	39/146 (26.7%)	33/139 (23.7%)	
	3	17/146 (11.6%)	18/139 (12.9%)	
	4	4/146 (2.7%)	13/139 (9.4%)	
Collateral score, median (IQR)		1 (1–2)	2 (1–2)	0.15 $\alpha$
		1 (1–2)	2 (1–3)	
Modified collateral score, median (IQR)		1 (1–2)	2 (1–3)	0.13 $\alpha$
		1 (1–2)	2 (1–3)	
Modified collateral score 0–2 vs 3–5	0–2	117/146 (80.1%)	99/139 (71.2%)	0.079 $\beta$
	3–5	29/146 (19.9%)	40/139 (28.8%)	
Modified collateral score 0–1 vs 2–5	0–1	78/146 (53.4%)	66/139 (47.5%)	0.32 $\beta$
	2–5	68/146 (46.6%)	73/139 (52.5%)	
Hypoperfusion intensity ratio, median (IQR)		0.51 (0.37–0.63)	0.41 (0.25–0.56)	<0.001 $\alpha$
Hypoperfusion intensity ratio >0.4		101/146 (69.2%)	72/139 (51.8%)	0.003 $\beta$
Time from last known well to procedure (hours), median (IQR)		3.70 (2.40–5.37)	4.08 (2.75–6.07)	0.090 $\alpha$
No. of passes	Single	70/142 (49.3%)	65/135 (48.1%)	0.85 $\beta$
	Multiple	72/142 (50.7%)	70/135 (51.9%)	
Type of anesthesia	General anesthesia	65/146 (44.5%)	64/139 (46.0%)	0.80 $\beta$
	Conscious sedation	81/146 (55.5%)	75/139 (54.0%)	
Time from groin puncture to successful reperfusion/end of procedure (Minutes), median (IQR)		34 (23, 57)	39 (27, 59)	0.069 $\alpha$

Results are shown as No (%) unless stated otherwise.  
 $\alpha$  - Wilcoxon rank-sum test,  $\beta$  - Pearson's  $\chi^2$  test,  $\gamma$  - Fisher's Exact test  
 ASPECTS, Alberta Stroke Program Early CT Score; ICA, internal carotid artery; MCA, middle cerebral artery; NIHSS, National Institutes of Health Stroke Scale.

(47%).<sup>22–26</sup> The differences in participation add to the limitations of the studies evaluating EVT outcomes and treatment effect disparities by sex across the world that originated from

these trials and further quantifies the need for an unbiased assessment of the impact of sex on EVT outcomes and treatment effect.

**Table 2** Baseline characteristics in a propensity-matched SELECT population treated with endovascular thrombectomy (EVT)

Factor	Level	Men	Women	P value
N		65	65	
Age, median (IQR)		64 (54–74)	67 (52–76)	0.56 $\alpha$
Serum glucose (mg/dL), median (IQR)		120 (107–157)	125 (108–154)	0.78 $\alpha$
Hypertension		43/65 (66%)	46/65 (71%)	0.57 $\beta$
Congestive heart failure		7/65 (11%)	5/65 (8%)	0.54 $\beta$
Coronary artery disease		9/65 (14%)	12/65 (18%)	0.47 $\beta$
Atrial fibrillation		19/65 (29%)	17/65 (26%)	0.70 $\beta$
Diabetes mellitus		15/65 (23%)	16/65 (25%)	0.84 $\beta$
Transient ischemic attack		4/65 (6%)	4/64 (6%)	>0.99 $\gamma$
Prior stroke		9/65 (14%)	8/63 (13%)	0.85 $\beta$
Current smokers		9/61 (15%)	7/62 (11%)	0.57 $\beta$
Past smokers		11/60 (18%)	11/62 (18%)	0.93 $\beta$
Clot location	ICA	9/65 (14%)	10/65 (15%)	0.38 $\beta$
	MCA-M1	35/65 (54%)	41/65 (63%)	
	MCA-M2	21/65 (32%)	14/65 (22%)	
Transfer status		26/65 (40%)	27/65 (42%)	0.86 $\beta$
Time from last known well to arrival to EVT-capable center (hours), median (IQR)		2.23 (0.75–3.83)	2.40 (1.10–4.33)	0.22 $\alpha$
IV Alteplase administered		41/65 (63%)	41/65 (63%)	1.00 $\beta$
NIHSS score, median (IQR)		15 (12–20)	16 (10–20)	0.76 $\alpha$
ASPECTS on baseline CT, median (IQR)		8 (7–9)	8 (7–9)	0.71 $\alpha$
Ischemic core volume (mL), median (IQR)		6 (0–21)	12 (0–25)	0.30 $\alpha$
Tissue volume with Tmax >6s (mL), median (IQR)		131.0 (94.0–200.1)	109.0 (66.0–141.0)	0.007 $\alpha$
Tissue volume with Tmax >10s (mL), median (IQR)		68.7 (28.4–121.2)	43 (20–73.7)	0.044 $\alpha$
Collateral score	0	4/65 (6%)	1/65 (2%)	0.60 $\gamma$
	1	30/65 (46%)	32/65 (49%)	
	2	23/65 (35%)	22/65 (34%)	
	3	3/65 (5%)	6/65 (9%)	
	4	5/65 (8%)	4/65 (6%)	
Modified collateral score	0	4/65 (6%)	1/65 (2%)	0.73 $\gamma$
	1	30/65 (46%)	32/65 (49%)	
	2	16/65 (25%)	16/65 (25%)	
	3	7/65 (11%)	6/65 (9%)	
	4	3/65 (5%)	6/65 (9%)	
Collateral score, median (IQR)		1 (1–2)	1 (1–2)	0.62 $\alpha$
		1 (1–2)	1 (1–2)	
Modified collateral score, median (IQR)		1 (1–2)	1 (1–2)	0.65 $\alpha$
		1 (1–2)	1 (1–2)	
Modified collateral score 0–2 vs 3–5	0–2	50/65 (77%)	49/65 (75%)	0.84 $\beta$
	3–5	15/65 (23%)	16/65 (25%)	
Modified collateral score 0–1 vs 2–5	0–1	34/65 (52%)	33/65 (51%)	0.86 $\beta$
	2–5	31/65 (48%)	32/65 (49%)	
Hypoperfusion intensity ratio, median (IQR)		0.48 (0.31–0.63)	0.42 (0.30–0.56)	0.44 $\alpha$
Hypoperfusion intensity ratio >0.4		37/65 (57%)	37/65 (57%)	1.00 $\beta$
Time from last known well to procedure (hours), median (IQR)		3.80 (2.28–5.23)	3.83 (2.70–5.98)	0.36 $\alpha$
No. of passes	Single	31/64 (48%)	27/63 (43%)	0.53 $\beta$
	Multiple	33/64 (52%)	36/63 (57%)	
Type of anesthesia	General Anesthesia	27/65 (42%)	26/65 (40%)	0.86 $\beta$
	Conscious Sedation	38/65 (58%)	39/65 (60%)	
Time from groin puncture to successful reperfusion/end of procedure (Minutes), median (IQR)		32 (21–56)	39 (30–59)	0.052 $\alpha$

Results are shown as No (%) unless stated otherwise.

 $\alpha$  - Wilcoxon rank-sum test,  $\beta$  - Pearson's  $\chi^2$  test,  $\gamma$  - Fisher's Exact test

ASPECTS, Alberta Stroke Program Early CT Score; ICA, internal carotid artery; MCA, middle cerebral artery; NIHSS, National Institutes of Health Stroke Scale.

Similarly, prior reports on EVT outcomes and potential treatment effect by sex have been conflicting. A subanalysis from the HERMES patient-level meta-analysis showed similar treatment effect of thrombectomy by sex,<sup>27</sup> while an analysis from

MR CLEAN data showed better outcomes in men.<sup>9</sup> In a post hoc analysis of the DEFUSE 3 trial, 35% of women but 54% of men who underwent EVT in the late window were functionally independent at 90 days.<sup>12</sup> Another analysis that combined data

**Table 3** Clinical outcomes in a propensity-matched SELECT population treated with endovascular thrombectomy (EVT)


Factor	Men	Women	aOR (95% CI)	P value
N	65	65		
mRS score at discharge, median (IQR)	3 (1–4)	3 (1–4)	0.86 (0.44 to 1.71) $\alpha$	0.67
mRS score at 90 days, median (IQR)	1 (0–4)	3 (1–4)	0.49 (0.25 to 0.96) $\alpha$	0.04
Good outcomes (mRS score 0–2) at discharge, n (%)	31 (48%)	27 (42%)	0.55 (0.18 to 1.69) $\beta$	0.30
Good outcomes (mRS score 0–2) at 90 days, n (%)	39 (60%)	30 (46%)	0.41 (0.16 to 1.00) $\beta$	0.05

$\alpha$  - Assessed using ordinal logistic regression,  $\beta$  - assessed using logistic regression  
mRS, modified Rankin Scale.

from the SWIFT (Solitaire With the Intention For Thrombectomy), STAR (Solitaire Thrombectomy for Acute Revascularization), and SWIFT PRIME (Solitaire With the Intention For Thrombectomy as Primary Endovascular Treatment) cohorts reported similar functional independence rates between men and women at 90 days and found that women had more years of optimal life (disability-adjusted life year) after EVT.<sup>28</sup> Differences in EVT outcomes when comparing men to women in these studies may in part be due to differences in the baseline clinical and imaging characteristics, as well as the design and enrollment criteria for the individual trials. There are baseline clinical and imaging characteristics that demonstrate significant differences between two sexes due to natural history of the stroke. Thus, women generally present later in life, and have significantly different imaging characteristics.<sup>12</sup> Our study differs from the aforementioned analyses evaluating effect of sex on EVT outcomes as we attempted to account for these differences by using a propensity-matched cohort. Furthermore, we evaluated outcomes at discharge and 90-day follow-up, but also characterized how the improvement from discharge to 90-day follow-up differs between the two sexes.


In our cohort, women had smaller perfusion deficit, better collaterals, and smaller core infarct at presentation. Additionally, women had a trend towards smaller follow-up infarct volumes after EVT in spite of similar successful reperfusion rates. The comparison of imaging characteristics by sex in the DEFUSE 3 trial<sup>12</sup> was consistent with our findings as women had better collaterals, smaller presentation core volumes, and slower infarct growth than men. Women, however, still had lower functional independence rates in DEFUSE 3. This highlights the importance of factors other than reperfusion, such as baseline imaging and clinical variables, that might affect thrombectomy outcomes. To mitigate the impact of potential baseline clinical and imaging factors, we performed a propensity-matched analysis and found better improvement in men from discharge to 90-day follow-up than in women. A prior single-center study also reported similar

functional independence rates at discharge, but less likelihood of women being independent at 90 days.<sup>29</sup> That study, however, included patients with both anterior and posterior circulation LVO and allowed for patients with baseline disability (mRS score >2) in the analysis. These findings highlight potential disparities in post-discharge care between men and women. Although the discharge disposition did not differ between the two sexes in our study, it is plausible that several social, psychological, and physical factors affected the post-discharge recovery



**Figure 1** Distribution of modified Rankin Scale (mRS) scores at discharge and 90-day follow-up, stratified by sex in propensity-matched SELECT population treated with endovascular thrombectomy. While the distribution of mRS scores did not differ at discharge (adjusted common OR (cOR)=0.86, 95% CI 0.44 to 1.71, p=0.67), 90-day mRS scores were significantly worse in women (cOR=0.49, 95% CI 0.25 to 0.96, p=0.04).

Propensity- Matched Cohort



**Figure 2** Predicted improvement in modified Rankin Scale (mRS) scores from discharge to 90-day follow-up. In a propensity-matched SELECT cohort treated with endovascular thrombectomy, women demonstrate a significantly lower reduction in mRS scores than men: (A) in an unadjusted model, and (B) In a model adjusted for baseline differences and potential clinical and imaging confounders.

of women as compared with men, suggesting the need for more comprehensive surveillance of post-discharge health status in patients receiving EVT.

Women were older in our cohort. Frailty renders older individuals more prone to adverse health outcomes, and women are shown to be disproportionately affected by frailty.<sup>30 31</sup> Prior studies have demonstrated that women had higher frailty at the time of stroke incidence, leading to worse outcomes.<sup>32</sup>

Women and men in our cohort had similar discharge rates to acute inpatient rehabilitation. Prior reports showed better response to acute rehabilitation in women than in men. However, other potential factors, including higher rates of social isolation with consequent negative effects on outcomes,<sup>33</sup> might have contributed to women having lower improvement rates with post-stroke rehabilitation. In the animal models, social isolation was associated with poor functional recovery after stroke.<sup>34</sup> According to 2010 census data, 51% of women versus 71% of men over the age of 55 have a spouse present at home.<sup>35</sup> Studies have also shown that women are at a higher risk of experiencing widowhood than men,<sup>36</sup> which might contribute to worse post-stroke cognitive outcomes in women.<sup>37</sup>

Moreover, with post-stroke depression being a significant risk factor for worse outcomes, the severity of depressive symptoms has been found to be greater in women following stroke.<sup>38 39</sup>

The differential natural history of stroke based on sex means that there will be differences in the clinical characteristics of men and women participating in acute ischemic stroke trials, which may eventually affect their short and long-term clinical outcomes. Our study demonstrated significantly different post-discharge progression after EVT in a matched prospective cohort, presenting at nine high-volume EVT centers across the USA. This may highlight the need to actively identify potential sex-related disparities and measures to minimize them in longitudinal studies to prevent potential bias affecting clinical trials evaluating EVT outcomes and treatment benefits, including provision of external support and standardization of secondary stroke prevention and post-stroke rehabilitation.

Post-discharge longitudinal studies are necessary to assess the frequency and duration of rehabilitation and the psychobehavioral, socioeconomic, and biological factors that affect the benefit from rehabilitation and post-discharge improvement after thrombectomy. These studies would assess these influences on sex/gender disparities and provide insights on potential interventions to maximize post-discharge recovery after thrombectomy.

The SELECT trial was primarily designed to evaluate imaging profiles and their effect on functional and safety outcomes after acute ischemic stroke, but the presence of significant differences in various imaging characteristics between men and women based on the natural history of stroke, together with prospective design and consecutive enrollment of patients at nine high-volume EVT centers in the USA, make the data unique in its ability to evaluate the question under consideration.

Our study has several limitations. This was a retrospective secondary analysis from a prospective cohort study, and thus might have carried the potential inherent limitations of these types of analyses. As the study represent an analysis of non-randomized data, we refrained from evaluating sex differences in EVT treatment effect. Furthermore, the SELECT trial enrolled patients between January 2016 and February 2018. Recent advances in the field of post-discharge care for acute ischemic stroke, including remote delivery of rehabilitation through telemedicine, might affect the findings of the study. We also did not evaluate the effect of stroke laterality on potential post-discharge progression. Insurance status and disposition at 90-day follow-up was not available for analysis.

Additionally, we lacked the sociobehavioral, socioeconomic, and psychological variables that might have explained the differences in outcomes. Clinical and imaging characteristics were significantly different between men and women and might have influenced the outcomes. To reduce the influence of these factors a propensity-matched analysis was preferred and executed. Despite this, our hypothesis-generating study sheds light on the potential differences in post-thrombectomy improvement in women as compared with men with the potential disparities in post-acute stroke care by sex.

## CONCLUSION

In a propensity-matched cohort of men and women from the SELECT study, women had similar discharge outcomes to those of men following EVT. The improvement from discharge to 90-day follow-up, however, was significantly worse in women, suggesting the influence of factors affecting post-discharge recovery. Further exploration of this phenomenon to identify targeted interventions is warranted.

### Author affiliations

<sup>1</sup>Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA

<sup>2</sup>Department of Neurology, Boston Medical Center, Boston, Massachusetts, USA

<sup>3</sup>Department of Neurology, Rush University Medical Center, Chicago, Illinois, USA

<sup>4</sup>Department of Neurology, University of Texas McGovern Medical School, Houston, Texas, USA

<sup>5</sup>Department of Neurology, University Hospitals Neurological Institute, Cleveland, Ohio, USA

<sup>6</sup>Department of Neurology, Baylor Scott & White Health, Dallas, Texas, USA

<sup>7</sup>Department of Neurology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA

<sup>8</sup>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA

<sup>9</sup>Department of Physical Medicine and Rehabilitation, The University of Texas Southwestern Medical Center, Dallas, Texas, USA

<sup>10</sup>Population and Data Sciences, The University of Texas Southwestern Medical Center, Dallas, Texas, USA

<sup>11</sup>Department of Neurology, Albert Einstein Medical Center, Philadelphia, Pennsylvania, USA

<sup>12</sup>Department of Neurology, Infirmary and New Orleans East Hospital, Metairie, Louisiana, USA

<sup>13</sup>Dr. Brain Inc, New Orleans, Louisiana, USA

<sup>14</sup>Medicine - Division Neurology, Toronto Western Hospital, Toronto, Ontario, Canada

<sup>15</sup>Department of Neurological Surgery, Spectrum Health Medical Group, Grand Rapids, Michigan, USA

<sup>16</sup>Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA

<sup>17</sup>Department of Neurological Surgery, Thomas Jefferson University Hospitals, Wayne, Pennsylvania, USA

<sup>18</sup>Department of Neurology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

**Twitter** Faris Shaker @Faris\_Shaker and Amrou Sarraj @amrsarrajMD

**Acknowledgements** This study was a secondary analysis of the SELECT trial data. The authors would like to acknowledge the contribution from the site investigators and coordinators, who supported the enrollment in the SELECT trial at UT McGovern Medical School – Houston, Texas; Emory University – Atlanta, Georgia; Florida Hospital – Orlando, Florida; Stanford University, Palo Alto, California; St Louis University – St. Louis, Missouri; Kansas University – Kansas City, Kansas; Valley Baptist Hospital – Harlingen, Texas; Riverside Methodist Hospital – Columbus, Ohio; and WellStar Health System - Marietta, Georgia.

**Contributors** ASa designed and conceptualized the research and provided administrative and material support and as a guarantor accepts full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish. ASa, JTF, and TNN drafted the manuscript. DKP contributed to the data analysis. SS, ASH, FS, LEF, EMJ, CGL, SJS, NLI, MVD, SM-S, JS, JPT, AWA, and SIT provided critical revisions of the manuscript for important intellectual content.

**Funding** The SELECT trial (Optimizing Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke) was funded by Stryker Neurovascular through a grant to UT McGovern Medical School.

**Competing interests** ASa reports serving as the principal investigator of the SELECT (Optimizing Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke) and SELECT-2 trials through a grant from Stryker Neurovascular to University of Texas McGovern-Houston; as a consultant, speaker bureau member, and advisory board member for Stryker; and as a site principal investigator for the TREVO Registry and DEFUSE 3 trials (Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke). JTF is a member of the editorial boards of the Journal of NeuroInterventional Surgery (JNIS), and reports receiving consulting fees from Stryker outside this research work. SIT is an editorial board member of JNIS. TNN reports receiving research support from Medtronic and the Society of Vascular and Interventional Neurology outside this work.

**Patient consent for publication** Not applicable.

**Ethics approval** This study involves human participants and was approved by UT McGovern Medical School – Houston, Texas - UT Committee for Protection of Human Subjects (HSC-MS-15-0337), Emory University – Atlanta, Georgia: Emory University IRB (CR1\_IRB00083782); Florida Hospital – Orlando, Florida: Florida Hospital IRB (699641-2), Stanford University, Palo Alto, California - Stanford IRB (37774); St. Louis University – St. Louis, Missouri - SLU IRB (26092), Kansas University – Kansas City, Kansas: KUMC IRB (IRB0000161); Valley Baptist Hospital – Harlingen, Texas - MetroWest Medical Center IRB (2015-095); Riverside Methodist Hospital – Columbus, Ohio: WIRB (1160694); and WellStar Health System - Marietta, Georgia: WIRB (1162531). Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

#### ORCID iDs

Thanh N Nguyen <http://orcid.org/0000-0002-2810-1685>

Deep Kiritbhai Pujara <http://orcid.org/0000-0001-6187-894X>

Faris Shaker <http://orcid.org/0000-0003-4462-5232>

Stavropoula I Tjoumakaris <http://orcid.org/0000-0002-1054-9414>

Amrou Sarraj <http://orcid.org/0000-0001-5726-4478>

#### REFERENCES

- Bushnell CD, Chaturvedi S, Gage KR, *et al.* Sex differences in stroke: challenges and opportunities. *J Cereb Blood Flow Metab* 2018;38:2179–91.
- Bushnell CD, Reeves MJ, Zhao X, *et al.* Sex differences in quality of life after ischemic stroke. *Neurology* 2014;82:922–31.
- Appelros P, Stegmayr B, Terént A. A review on sex differences in stroke treatment and outcome. *Acta Neurol Scand* 2010;121:359–69.
- Girijala RL, Sohrabji F, Bush RL. Sex differences in stroke: review of current knowledge and evidence. *Vasc Med* 2017;22:135–45.
- Persky RW, Turtzo LC, McCullough LD. Stroke in women: disparities and outcomes. *Curr Cardiol Rep* 2010;12:6–13.
- Phan HT, Blizzard CL, Reeves MJ, *et al.* Sex differences in long-term quality of life among survivors after stroke in the INSTRUCT. *Stroke* 2019;50:2299–306.
- Petrea RE, Beiser AS, Seshadri S, *et al.* Gender differences in stroke incidence and poststroke disability in the Framingham heart study. *Stroke* 2009;40:1032–7.
- Strong B, Lisabeth LD, Reeves M. Sex differences in IV thrombolysis treatment for acute ischemic stroke: a systematic review and meta-analysis. *Neurology* 2020;95:e11–22.
- de Ridder IR, Franssen PSS, Beumer D, *et al.* Is intra-arterial treatment for acute ischemic stroke less effective in women than in men? *Interv Neurol* 2016;5:174–8.
- Chalos V, de Ridder IR, Lingsma HF, *et al.* Does sex modify the effect of endovascular treatment for ischemic stroke? *Stroke* 2019;50:2413–9.
- Madsen TE, DeCrose-Movson E, Hemendinger M, *et al.* Sex differences in 90-day outcomes after mechanical thrombectomy for acute ischemic stroke. *J Neurointerv Surg* 2019;11:221–5.
- Dula AN, Mlynash M, Zuck ND, *et al.* Neuroimaging in ischemic stroke is different between men and women in the DEFUSE 3 cohort. *Stroke* 2020;51:481–8.
- Sheth SA, Lee S, Warach SJ, *et al.* Sex differences in outcome after endovascular stroke therapy for acute ischemic stroke. *Stroke* 2019;50:2420–7.
- Davison MA, Ouyang B, Keppetipola KM, *et al.* Arterial diameter and the gender disparity in stroke thrombectomy outcomes. *J Neurointerv Surg* 2018;10:949–52.
- Hay CC, Graham JE, Pappadis MR, *et al.* The impact of one's sex and social living situation on rehabilitation outcomes after a stroke. *Am J Phys Med Rehabil* 2020;99:48–55.
- Dong L, Briceno E, Morgenstern LB, *et al.* Poststroke cognitive outcomes: sex differences and contributing factors. *J Am Heart Assoc* 2020;9:e016683.
- Sarraj A, Hassan AE, Savitz S, *et al.* Outcomes of endovascular thrombectomy vs medical management alone in patients with large ischemic cores. *JAMA Neurol* 2019;76:1147.
- Sarraj A, Hassan AE, Grotta J, *et al.* Optimizing patient selection for endovascular treatment in acute ischemic stroke (SELECT): a prospective, multicenter cohort study of imaging selection. *Ann Neurol* 2020;87:419–33.
- Powers WJ, Rabinstein AA, Ackerson T, *et al.* Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2019;50:e344–418.
- Zaidat OO, Yoo AJ, Khatri P, *et al.* Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. *Stroke* 2013;44:2650–63.
- Hacke W, Kaste M, Bluhmki E, *et al.* Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. *N Engl J Med* 2008;359:1317–29.
- Saver JL, Goyal M, Bonafe A, *et al.* Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. *N Engl J Med* 2015;372:2285–95.
- Nogueira RG, Jadhav AP, Haussen DC, *et al.* Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. *N Engl J Med* 2018;378:11–21.
- Albers GW, Marks MP, Kemp S, *et al.* Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. *N Engl J Med* 2018;378:708–18.
- Berkhemer OA, Fransen PSS, Beumer D, *et al.* A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med* 2015;372:11–20.
- Jovin TG, Chamorro A, Cobo E, *et al.* Thrombectomy within 8 hours after symptom onset in ischemic stroke. *N Engl J Med* 2015;372:2296–306.
- Chalos V, de Ridder IR, Lingsma HF, *et al.* Does sex modify the effect of endovascular treatment for ischemic stroke? *Stroke* 2019;50:2413–9.
- Sheth SA, Lee S, Warach SJ, *et al.* Sex differences in outcome after endovascular stroke therapy for acute ischemic stroke. *Stroke* 2019;50:2420–7.
- Madsen TE, DeCrose-Movson E, Hemendinger M, *et al.* Sex differences in 90-day outcomes after mechanical thrombectomy for acute ischemic stroke. *J Neurointerv Surg* 2019;11:221–5.
- Fried LP, Tangen CM, Walston J, *et al.* Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci* 2001;56:M146–57.
- Bergman H, Ferrucci L, Guralnik J, *et al.* Frailty: an emerging research and clinical paradigm—issues and controversies. *J Gerontol A Biol Sci Med Sci* 2007;62:731–7.
- Gordon EH, Peel NM, Samanta M, *et al.* Sex differences in frailty: a systematic review and meta-analysis. *Exp Gerontol* 2017;89:30–40.
- Paradiso S, Robinson RG. Gender differences in poststroke depression. *J Neuropsychiatry Clin Neurosci* 1998;10:41–7.
- Venna VR, Weston G, Benashski SE, *et al.* NF- $\kappa$ B contributes to the detrimental effects of social isolation after experimental stroke. *Acta Neuropathol* 2012;124:425–38.
- Age and sex composition in the United States: 2010, 2011. Available: <https://www.census.gov/data/tables/2010/demo/age-and-sex/2010-age-sex-composition.html> [Accessed 11 Nov 2020].
- Lee GR, DeMaris A, Bavin S, *et al.* Gender differences in the depressive effect of widowhood in later life. *J Gerontol B Psychol Sci Soc Sci* 2001;56:S56–61.
- Dong L, Briceno E, Morgenstern LB, *et al.* Poststroke cognitive outcomes: sex differences and contributing factors. *J Am Heart Assoc* 2020;9:e016683.
- Mazure CM, Weinberger AH, Pittman B, *et al.* Gender and stress in predicting depressive symptoms following stroke. *Cerebrovasc Dis* 2014;38:240–6.
- Zalihić A, Markotić V, Zalihić D, *et al.* Gender and quality of life after cerebral stroke. *Bosn J Basic Med Sci* 2010;10:94–9.